As the latest generation in the XIENCE™ family of stents, the stent platform that consistently delivers successful patient outcomes – not only in the cath lab, but also long-term.4 This stent also offers:
The broadest expansion range among XIENCE™ Stents2
The largest size range for a single XIENCE™ product, from 8 mm to 48 mm2
During percutaneous coronary interventions (PCI), small differences between stents can be the determining factor for the patient’s acute and long-term outcomes.4 XIENCE Skypoint™ Stent has a number of new features that offer broader treatment options to interventional cardiologists (ICs).
Updated features include:
Larger stent expansion and enhanced stent design2
Slimmer catheter profile with integrated one-piece shaft5
Low crossing forces and excellent pushability6
Improved catheter hub5
New and improved stent design for 48-mm sizes7
These new features can help clinicians treat the increasingly wide range of lesions encountered in real-world patients.
XIENCE Skypoint™ Stent Retains Proven Design Elements
Compared to other DES, several key factors account for XIENCE™ Stent’s unparalleled clinical outcomes.1
Innovative Stent Design:
The XIENCE™ Stent is designed to conform to vessel anatomy,8 as well as to reduce inflammation and minimize thrombogenicity.9Get more details about the stent design.
Anti-Thrombotic Fluoropolymer:
Unlike other stents’ polymer coatings, the Abbott fluoropolymer interacts with blood proteins in a manner that reduces thrombus formation.9View the visual evidence of fluoropolymer safety—significantly less inflammation and thrombus formation—compared to competitors’ stents.
See more detail about XIENCE Skypoint™ Stent expansion, deliverability, and successful patient outcomes, not only during the PCI but far into the future.4
Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
Data on file at Abbott.
Tests performed by and data on file at Abbott—3.0 x 18 mm or 20 mm stents tested using a simulated arterial model. Comparison is between XIENCE Skypoint™ Stent, XIENCE Sierra™ Stent, Synergyǂ and Resolute Onyxǂ. Push efficiency comparison is between XIENCE Skypoint™ 48-mm Stent, XIENCE Xpedition™ 48-mm Stent and Synergyǂ 48 mm.
Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333.
Data on file at Abbott.
Tests performed by and data on file at Abbott. Crossing force comparison is between XIENCE Skypoint™ Stent, Synergyǂ and Resolute Onyxǂ—3.0 x 18 mm or 20 mm stents tested. Push efficiency comparison is between XIENCE Skypoint™ Stent, XIENCE Xpedition™ Stent, and Synergyǂ – 3.0 x 48 mm for all stents tested.
Data on file at Abbott.
Colombo A, et al. J Am Coll Cardiol. 2002;40:1021-1033.
Jinnouchi H, et al. J Am Coll Cardiol. 2019;74:(Suppl B):TCT-291.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
